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Soluble CD40 Ligand Predicts Ischemic Stroke and
Myocardial Infarction in Patients With Nonvalvular
Atrial Fibrillation
Domenico Ferro, Lorenzo Loffredo, Licia Polimeni, Filippo Fimognari, Paolo Villari,
Pasquale Pignatelli, Valentin Fuster, Francesco Violi
Objective—Atrial fibrillation (AF) is associated with a high incidence of vascular disease that may be related to a
prothrombotic and inflammatory state. Soluble CD40 ligand (sCD40L), which stems essentially from platelet activation,
possesses inflammatory and prothrombotic properties. The aim of the study was to assess whether sCD40L is a predictor
of stroke or myocardial infarction (MI) in patients with nonvalvular AF.
Methods and Results—Plasma levels of sCD40L were measured in 231 patients (177 [77%] had permanent or persistent
AF, and 54 [23%] had paroxysmal AF). Patients were followed for a mean period of 27.88.8 months, and
cardiovascular events such as fatal and nonfatal stroke and MI were recorded. AF population was divided in 2 groups
according to sCD40L level above or below the median (4.76 ng/mL). The 2 patients’ groups had similar distribution of
cardiovascular risk factors, age, gender, medications, or serum C-reactive protein levels. During the follow-up period,
vascular events occurred in 6 (2 nonfatal MI and 4 nonfatal ischemic strokes) of 116 patients with low levels of sCD40L
(5.1%) and in 29 (11 fatal and 3 nonfatal MI; 3 fatal and 12 nonfatal ischemic strokes) of 115 patients with high levels
(25.2%) (log-rank test: P0.001). Using the COX proportional Hazards model, patients with sCD40L above the median
were 4.63 times more likely to experience a vascular event (95% C.I.: 1.92 to 11.20).
Conclusions—This study shows that enhanced soluble CD40L level is a predictor of vascular events in patients with
nonvalvular AF, thus suggesting that enhanced platelet activation may play a role in its clinical progression.
(Arterioscler Thromb Vasc Biol. 2007;27:2763-2768.)
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Nonvalvular atrial fibrillation (AF) is the most commoncause of cardiac arrhythmia and is known to be associ-
ated with both thromboembolic and cardiovascular events.1 In
particular, patients with AF have about 5-fold increase of
stroke risk, which is prevalently dependent on thrombosis
occurring in the left atrium or left atrium appendage.2 In
addition to thromboembolic stroke patients with AF have a
clinical history that is also complicated by other cardiovas-
cular events including myocardial infarction (MI) and vascu-
lar death.3 This is likely dependent on the fact that AF
patients often show several risk factors for atherosclerosis
such as hypertension and diabetes, which may favor the
occurrence of coronary atherosclerosis and eventually MI.4
Oral anticoagulants or aspirin are established antithrom-
botic treatments to prevent thromboembolism in AF patients.5
However, despite the fact that oral anticoagulants reduce by
more than 50% the risk of stroke,6 there is still a large number
of patients, particularly those at high risk, who may not
benefit from anticoagulant treatment. Therefore, identifica-
tion of these patients, who are still at high risk of cardiovas-
cular events despite antithrombotic treatment, could be useful
to develop more appropriate prevention.
Platelet activation is a typical feature of patients with and
at risk of developing cardiovascular events. Abnormal plate-
let activation has been observed in patients with AF particu-
larly in case of coexistence of embolic or preembolic status.7
This would suggest that platelet activation may be a marker
of thromboembolic stroke in AF patients but the data so far
reported are inconclusive.8
CD40 ligand (CD40L) is a protein of the tumor necrosis
factor family that is implicated in the pathogenesis of athero-
sclerosis via its inflammatory and prothrombotic proper-
ties.9–11 CD40L is expressed in hematopoietic cell types such
as T lymphocytes, monocytes, or platelets and nonhemato-
poietic cells such as endothelial and smooth muscle cells.9,12
A lot of attention has been recently given to the clinical
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validity of soluble CD40L (sCD40L), which derives preva-
lently from platelet activation,13 as a marker of cardiovascular
events. Notably, sCD40L highly correlates with instable
plaque and may be an important predictor of plaque instabil-
ity and eventually plaque complication.14,15 Observational
and prospective studies supported this view by showing that
sCD40L is a predictor of cardiovascular events including MI
and stroke.16–18
There are several reasons that could render attractive the
analysis of sCD40L in AF. In fact AF is associated with both
platelet and clotting activation, which may be favored by
CD40L19 and potentially contribute to thrombus formation.
Also, CD40L has inflammatory properties that could deteri-
orate the clinical course of AF by precipitating cardiovascular
events. Accordingly, a previous study demonstrated that
plasma levels of the inflammatory protein interleukin (IL) 6
predict vascular events in a population with AF.20 Based on
these findings we undertook a prospective study in which we
analyzed if sCD40L predict cerebro- and cardiovascular
events in a population with AF.
Methods
Two hundred thirty-one eligible subjects were recruited, between
April 2001 and September 2006, from among consecutive patients
admitted to the IV Division of Clinical Medicine because of
nonvalvular AF—paroxysmal, persistent, or permanent (lasting 6
months). Of the 231 patients recruited, 177 (77%) had permanent or
persistent AF, and 54 (23%) had paroxysmal AF.
Patient Selection
Patients were excluded if they had rheumatic AF; other cardiac
reasons for exclusion were echocardiographic evidence of intracar-
diac thrombosis or tumor; left ventricular aneurysm, severe conges-
tive heart failure (New York Heart Association functional class 3),
or the presence of prosthetic valves; acute myocardial infarction or
unstable angina during the previous month; carotid endarterectomy
or coronary or peripheral revascularization procedures performed
during the previous 6 months; acquired or congenital valvular
disease (except mitral valve prolapse or mitral annulus calcification).
The neurological exclusion criteria included CT brain scan evidence
of cerebral hemorrhage, documented arteriovenous malformation or
tumor, severe involutive cerebral disease, or the presence of a carotid
lesion requiring surgical intervention.
According to ACC/AHA/ESC guidelines for the management of
patients with atrial fibrillation, patients were classified as having
low, moderate, or high risk for ischemic stroke.5 Based on this
classification 172 patients (74.4%) were treated with oral anticoagu-
lants and 55 (23.8%) with aspirin (100 mg/d). Each patient gave
informed consent to participate in the study, that was approved by
the Ethical Committee.
Baseline
At entry, each patient’s medical history was taken and he/she
underwent a physical examination. The following diagnostic proce-
dures were also performed: routine blood laboratory tests, baseline
12-lead ECG, M-mode, and 2-dimensional echocardiography with
echocolor-doppler, echocolor-doppler of the supra-aortic trunks, and
chest roentgenography.
Follow-Up
Patients were periodically monitored (every 3 months) to assess
compliance and clinical status, ECG, and laboratory tests (anticoag-
ulant treatment was adjusted to ensure INR values within the range
of 2.0 to 3.0), and a record was made of the occurrence of any
outcome events, the degree of disability, the appearance of any
adverse drug reactions, and the patient’s compliance with the
prescribed drugs. All deaths and their causes were recorded, with
death certificates being obtained in the case of deaths occurring
outside the hospital.
Outcome Events
The combined incidence of the following vascular events was
considered the primary outcome of the study: nonfatal and fatal
stroke, fatal and nonfatal myocardial infarction. A diagnosis of
myocardial infarction required at least 2 of the following criteria:
history of chest discomfort, development of a pathological Q wave
on ECG tracings, and elevation of specific cardiac enzymes to values
of more than twice the upper normal limit. The occurrence of stroke
was determined on the basis of clinical manifestations and confirmed
by CT. If a patient died within 4 weeks of an acute vascular event,
this was recorded as cardiovascular death attributable to an ischemic
event.
Blood Collection and Laboratory Analysis
Blood sample was withdrawn without stasis to minimize platelet
activation from subjects who had fasted for 12 hours, directly mixed
in a vacutainer (Vacutainer Systems, Belliver Industrial Estate) with
1 part of 3,8% Na citrate (ratio 9:1) and immediately centrifuged for
20 minutes at 2000g at4°C. Plasma samples were stored at80°C
until use.
Plasma levels of sCD40L were evaluated behind an immunoassay
(Quantikine CD40 ligand, R&D Systems). Intraassay and interassay
coefficients of variation were 6% and 7%, respectively.
Serum high-sensitivity C-reactive protein (CRP) was assayed by
an immunonephelometric method (N-High Sensitivity CRP, Dade
Behring Marburg Gmbh). Intra- and interassay coefficients of
variation were 3 and 2.5%, respectively.
Statistical Analysis
Two-sided t test was used to compare means. Results were con-
firmed by nonparametric tests as Wilcoxon rank sum. Pearson
chi-square test was used to compare proportions.
To evaluate whether high levels of sCD40L were associated with
different degree of ischemic risk, the AF population was divided into
2 groups: patients above or below the median (4.76 ng/mL). The
cumulative risk of vascular events (stroke and myocardial infarction)
within each group was estimated through the Kaplan–Meier method.
The survival curves of the 2 groups were then formally compared
using the log-rank test. The validity of constant incidence ratios over
the follow-up was checked using Nelson-Aalen cumulative hazard
estimates.21 Kaplan–Meier survival analysis was performed also to
compare the survival curves of patients in the highest quartile of
sCD40L versus patients of the other quartiles.
Cox proportional hazards analysis was used to calculate the
adjusted relative hazards of vascular events by each clinical variable.
The following variables, assessed at the baseline evaluation, were
considered as potential predictors of ischemic events: age, male, sex,
hypertension, diabetes, dyslipidemia, oral anticoagulant treatment,
antiplatelet treatment, previous cerebral ischemia, previous coronary
heart disease, CRP (above the median), and sCD40L 4.76 ng/mL.
Stochastic level of entry into the model was set at 0.10, and
interaction terms were explored for all variables in the final model.
A minimum events-to-variable ratio of 10 was maintained in
multivariate modeling to avoid overfitting, and Schoenfeld’s test was
performed to check the validity of proportional hazards assump-
tion.22 Cox analyses were performed for all vascular events, as well
as separately for cardio- and cerebrovascular events.
A probability value of 0.05 was considered significant for all
analyses, which were performed using STATA statistical software
version 8.0 (STATA corporation, College Station, TX).
Results
The mean age of the AF population was 72.410.3 years,
and 190 subjects (82.2%) were older than 65 years of age.
Half of the patients were male (48%). History of stroke and
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coronary heart disease was reported by 12.9% and 18.6%
of patients, respectively. About 73% of patients were
receiving antihypertensive treatment (1 or more medication):
diuretics (64.5%), ACE-inhibitors (51.0%), Angiotensin-
renin blockers (12.1%), calcium-antagonists (46.7%), and
-blockers (29.4%).
To evaluate whether elevated levels of sCD40L indicated
an increased risk of cardiovascular and cerebrovascular
events, the AF population was divided into 2 groups on the
ground of the median value of sCD40L (4.76 ng/mL). The 2
groups had a similar distribution of cardiovascular risk
factors, age, gender, and clinical and laboratory markers of
risk factors; also, antiplatelet and anticoagulant drugs were
equally distributed between the 2 groups. Conversely, statin
treatment was more frequent in the group with high level of
sCD40L. The clinical history of previous stroke or coronary
heart disease was significantly higher in patients with levels
of sCD40L above the median (Table 1).
Patients were followed for a mean period of 27.88.8
months, yielding a total of 6434 person-months of observa-
tion. The follow-up period was not different in the 2 study
groups (28.67.6 and 27.19.8 months in patients with low
and high levels of sCD40L, respectively).
During the follow-up 35 patients (15.1%) experienced
cardiovascular and cerebrovascular events; 19 (8.2%) had
ischemic stroke, and 16 (6.9%) had MI. Vascular events
occurred in 6 (2 nonfatal MI and 4 nonfatal ischemic strokes)
of 116 patients with low levels of sCD40L (5.1%) and in 29
(11 fatal and 3 nonfatal MI; 3 fatal and 12 nonfatal ischemic
strokes) of 115 patients with high levels (25.2%).
Levels of sCD40L above the median were significantly
associated with shorter time to ischemic events (log-rank test:
P0.001; Figure 1). The association between high levels of
sCD40L and shorter time to ischemic events was even more
evident in the comparative evaluation of patients in the
highest quartile versus the others (log-rank test: P0.0005;
Figure 2).
The incidence rate of vascular events was 0.93 and 0.18 per
100 months of observation in patients with sCD40L levels
above and below the median, respectively. Using the Cox
proportional hazards model, after controlling for other vari-
ables, patients with sCD40L levels above the median were
4.63 times more likely to experience a vascular event (95%
C.I.: 1.92 to 11.20). The adjusted risk of vascular events
among patients with diabetes was 2.24 (95% C.I.:1.07 to
4.70; Table 2). No significant interactions were detected and
therefore were not included in the final model. High levels of
sCD40L and diabetes were independently related to vascular
events also when the Cox analysis was performed comparing
Table 1. Baseline Characteristics of Patients With Atrial Fibrillation According to the Level of Soluble
CD40 Ligand
Characteristics
Low Level of Soluble CD40
Ligand (4.76 ng/mL)
High Level of Soluble CD40
Ligand (4.76 ng/mL) P Value
No. of patients 116 115   
Male sex (%) 50 (43.1) 61 (53.0) 0.131
Mean age, y 71.311.2 73.59.3 0.103
Coronary artery disease 14 (12.1) 29 (25.2) 0.010
History of stroke or TIA 4 (3.5) 26 (22.6) 0.001
Cardiovascular risk factors (%)
Diabetes 17 (14.7) 20 (17.4) 0.571
Hypercholesterolemia 28 (24.1) 35 (30.4) 0.283
Hypertension 87 (75.0) 92 (80.0) 0.363
Current smoking 13 (11.2) 9 (7.8) 0.381
Risk stratification for ischemic (%)
High 88 (75.8) 97 (84.3) 0.800
Intermediate 18 (15.5) 14 (12.1) 0.586
Low 10 (8.6) 4 (3.4) 0.173
Medications at discharge (%)
Aspirin 31 (26.7) 24 (20.8) 0.373
Oral Anticoagulants 82 (70.6) 90 (78.2) 0.243
Statins 26 (22.4) 59 (51.3) 0.001
ACE inhibitors 55 (47.4) 63 (54.7) 0.323
Angiotensin type-1 receptor blockers 12 (10.3) 16 (13.9) 0.529
Calcium antagonists 56 (48.2) 52 (45.2) 0.641
Beta blockers 35 (30.1) 33 (28.6) 0.919
Diuretics 70 (60.3) 79 (68.1) 0.235
CRP (mg/L)* 3.65 (2.9–7.6) 3.9 (2.9–13.2) 0.400
Soluble CD40 ligand (ng/mL) 3.40.7 6.61.6 0.001
*Data expressed as median and interquartile range.
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patients in the highest quartile of sCD40L levels versus the
other (data not shown).
Cox analyses were performed also separately for cardio-
vascular and cerebrovascular events. Patients with sCD40L
levels above the median were 6.58 times more likely to
experience cardiovascular events (95% C.I.:1.49 to 29.11),
whereas the adjusted risk in patients with diabetes was 3.77
(95% C.I.:1.34 to 10.65). High levels of sCD40L, but not
diabetes, was related to cerebrovascular events (HR3.28;
95% C.I.:1.27 to 11.53), and the risk of cerebrovascular
events increased significantly with age (HR1.07; 95%
C.I.:1.01 to 1.14).
Discussion
This study provides evidence that plasma levels of sCD40L
are predictive of cardiovascular events including ischemic
stroke and MI in patients with AF.
The AF cohort screened encompassed prevalently high-
risk patients as more than 70% of patients had to be treated
with oral anticoagulants. During the follow-up of 3 years such
population experienced 8.2% ischemic stroke. This finding is
consistent with previous data showing that in patients treated
with adjusted-dosed warfarin stroke incidences range from
1.1% to 4% per year.23–26 In addition to ischemic stroke, our
population also suffered from coronary events with an inci-
dence rate of 6.9% during the observed period. Also this
finding is consistent with previous studies showing that a
relatively high percentage of patients with AF may suffer
from MI. The rate we observed is a little bit more than that
found in previous studies, where MI rate ranged from 0.6% to
1.4% per year23,24 but relatively close to an Italian study in
NVAF patients in which the annual rate of MI was 3.7%.26
Previous studies performed in patients with established
acute or chronic coronary heart disease documented that
plasma levels of sCD40L are predictive of atherosclerotic
progression.16,17,27 Such relationships seem to be relevant also
in patients with carotid atherosclerosis and in those with
obstructive sleep apnea.28,29
In the present study we analyzed the relevance of sCD40L
as predictor of cardiovascular events in AF patients. Here-
with, we demonstrated that patients with sCD40L above 4.7
ng/mL are at higher risk of ischemic stroke and MI compared
0.
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Figure 1. Kaplan–Meier estimates of time
to ischemic events by levels of sCD40L
(below and above the median).
0.
00
0.
25
0.
50
0.
75
1.
00
0 10 20 30 40 50
analysis time
sCD40L = other quartiles sCD40L = highest quartile
Figure 2. Kaplan–Meier estimates of time
to ischemic events by levels of sCD40L
(highest quartile vs other quartiles).
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with those with lower values. Such a relationship was
independent from other recognized risk factors such as age,
hypertension, diabetes, or previous history of cardiovascular
events. Another interesting finding of the study was that
sCD40L was an independent predictor of either ischemic
stroke or MI; however, because of the relatively small sample
size and the limited number of events such observation
should be wisely considered. It is intriguing, however, that
this molecule predicted 2 events that are prevalently caused
by different mechanisms: thromboembolic in the case of
ischemic stroke and atherothrombotic in the case of MI.
To exclude the existence of confounding factors related to
concomitant treatments, we checked for distribution of med-
ications that could affect sCD40L. Aspirin, for instance, has
been reported to reduce sCD40L.30 However, patients on
aspirin treatment were equally distributed between groups
with high or low sCD40L levels. We found, on the contrary,
a higher percentage of statin treatment in patients with high
sCD40L levels. Therefore, we cannot exclude that this could
have underestimated the predictive value of sCD40L as
statins have been shown to reduce sCD40L.31,32 Most patients
in our cohort were on an oral anticoagulant treatment.
However, we have previously found that oral anticoagulants
did not affect sCD40L in patients with lupus anticoagulant.33
Our data are apparently at variance with a recent study by
Lip et al34 which did not find any relationship between
sCD40L and cardiovascular events in a population with AF.
Different population and methodology of the study may
perhaps account for such divergence. Whereas our cohort
included prevalently patients at high risk of cardiovascular
events, most patients in the Lip’s trial were on treatment with
aspirin. Therefore, we cannot exclude that sCD40L is not
useful to predict cardiovascular events in a population at low
risk. This hypothesis is consistent with another study per-
formed in a large apparently healthy population (the Dallas
trial) demonstrating that sCD40L is not useful to screen for
subclinical atherosclerosis in patients at low risk.35 Also,
duration of observation could have had a different impact on
the prognostic value of sCD40L, because our follow-up
(about 3 years) was much longer than that of the Lip’s study
(1 year).
Circulating levels of sCD40L are considered a marker of
platelet activation as more than 95% seems to be of platelet
origin.13 The reason why sC40L is more useful in predicting
cardiovascular events in this setting compared with other
molecules such as p-selectin36,37 may depend on the peculiar-
ity of its prothrombotic property. Thus, CD40L is able to
promote overexpression of tissue factor, a glycoprotein that
has a crucial role in the activation of coagulation cascade,38
and is implicated in the process of platelet aggregation via
binding to platelet glycoprotein (GP) IIb/IIIa.39 In virtue of
these biological characteristics, sCD40L are likely to reflect
both clotting activation and platelet aggregation occurring in
patients with AF and, hence, could better identify patients
more prone to cardiovascular complications.
AF is associated with an inflammatory state that may
concur in favoring cardiovascular complication. Plasma lev-
els of IL-6 are elevated in this setting and may predict
cardiovascular events.20 CD40L also has inflammatory prop-
erty including expression of adhesive molecule, chemokines,
and metalloproteinases,14 and this adds further to the possi-
bility that inflammation may predict poor cardiovascular
outcome in AF patients. Consistent with previous studies16,35
we found no relationship between CD40L and CRP indicat-
ing that they likely represent 2 different pathways of the
inflammatory status.
The study has potential limitation and implication. The
predictive value of sCD40L was calculated by combining 2
end points with probable different mechanism of disease, ie,
ischemic stroke and MI. Thus, it is unclear from our study
whether sCD40L is sensitive to vascular events of thrombo-
embolic or atherotrombotic origin. Larger sample size is,
therefore, necessary to evaluate whether sCD40L is predic-
tive of either ischemic stroke or MI.
A recent study in elderly population with AF confirmed
that, despite oral anticoagulants, these patients had a 5.9%
annual risk of major outcomes including stroke, MI, and
vascular death.40 This indicates that other therapeutic strate-
gies should be implemented to reduce such high risk. Our
data suggest to investigate whether sCD40L lowering by
appropriate therapy may be associated with a further reduc-
tion of cardiovascular events in elderly AF population.
In conclusion this study shows that sCD40L is able to
predict cardiovascular events including ischemic stroke and
MI in an AF population at high risk. These data cannot be
extrapolated to a population at low risk and further study is
necessary to investigate this issue. Analysis of this biomarker
may represent another approach to stratify the cardiovascular
risk in AF population.
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